Yann Bergé

Learn More
PURPOSE We conducted a phase I dose-escalation study to characterize the safety, efficacy, pharmacokinetic (PK), and pharmacodynamic properties of RG7160 (GA201), a humanized and glycoengineered immunoglobulin G(1) anti-epidermal growth factor receptor (EGFR) monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity. PATIENTS AND(More)
10048 Background: The aim of this work was to characterize patient (pts) characteristics and the mutational status of GIST who benefit the most from IM in term of prolonged response and overall survival. METHODS Among the 434 pts included between June 2002 to July 2009 in the prospective multicentric BFR14 trial, we selected the 236 pts having started IM(More)
2585 Background: Afatinib (BIBW 2992) is an oral irreversible ErbB family blocker with activity in a wide range of tumor cell lines dependent on erbB signaling. Vinorelbine, a semi-synthetic vinca alkaloid, interferes with tubulin polymerization and spindle formation during metaphase. Additive or supraadditive activity of afatinib or EGFR TKI with(More)
AIM Imgatuzumab (GA201) is a novel anti-epidermal growth factor receptor (anti-EGFR) antibody glycoengineered for enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). We investigated the efficacy of imgatuzumab in patients with EGFR-positive, KRAS-mutant advanced colorectal cancer. METHODS Patients received single-agent imgatuzumab (1400mg on(More)
Elucidating how cancer cells respond to antagonists of HER receptor family members is critical to understanding mechanisms of therapeutic resistance that arise in patients. In large part, resistance to such agents appears to arise from deregulation of the phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR pathway. mTOR-dependent phosphorylation of the(More)
BACKGROUND Heat-shock protein 990 (HSP990) is a potent and selective synthetic small-molecule HSP90 inhibitor. The primary objectives of this phase I first-in-human study were to determine dose-limiting toxicities (DLTs), maximum-tolerated dose (MTD) and recommended phase II dose (RP2D). Secondary objectives included characterisation of the safety profile,(More)
RhoB has been reported to exert positive and negative effects on cancer pathophysiology but an understanding of its role in breast cancer remains incomplete. Analysis of data from the Oncomine database showed a positive correlation between RhoB expression and positivity for both estrogen receptor alpha (ERα) and progesterone receptor (PR). This finding was(More)
10079 Background: Data regarding the management of patients with metastatic EHE are almost nonexistent. METHODS From 1990 to 2010, 78 adult patients (pts) with a confirmed diagnosis of EHE were referred to one of the 9 participating institutions, and their medical records reviewed. RESULTS Forty-two (54%) patients had metastatic disease. Median age was(More)
BACKGROUND Soft tissue sarcomas (STS) are rare tumours for which treatment options are limited in the advanced setting. Histone deacetylase inhibitors have shown activity in preclinical models of STS. METHODS We conducted a single-arm, open-label, multicentre phase II study to assess the efficacy and tolerability of panobinostat given orally, 40 mg thrice(More)